|Day Low/High||221.39 / 226.21|
|52 Wk Low/High||177.05 / 264.97|
But is a Teva turnaround still coming after the stock's 70% loss in the past five years?
RMPIA outperformed once gain during April.
Plus a possible setup in Amgen as earnings approach.
Screening Goldman Sachs' list of the top 20 stocks to see which ones are the best technical opportunities.
In this day and age, companies must be 'disruptors' or get left in the dust.
The RMPIA rose 10.5% during the first half of the current quarter.
RMPIA soared 9.9% for the month, led by 11 double-digit gainers.
Apple shares are up nearly 4% in after-hours trading.
What we have seen of late from a number of chip producers really might be interpreted as pre-recessionary.
So far 2019 is proving to be a year where things have a habit of working out right.
One of pharma's biggest CEO's talks M&A action on the exchange.
Do we have to run for the hills? Not necessarily.
After the very negative market environment the past few months it is refreshing and exciting to find a stock with some upside potential.
We're out in San Francisco this week covering the amazing innovations that so many companies reveal at this annual conference.
Big pharma could be primed for an M&A Boom after Bristol-Myers Squibb's blockbuster deal for Celgene.
Take upbeat outlooks for equities with a grain of salt, and try these sectors to stay safe.
For the month of November RMPIA climbed 1.2% month over month.
Pfizer pushes higher on price increases.
Pharma could be the best parking spot for your money if the market keeps trending downward.
Investors should continue to hold Amgen.
Once the safest stocks in the book, the big-cap drug companies are now toxic.
My target price and panic points have changed, and I am watching for a chance to add or shave some off, depending on which direction the stock takes.
It becomes difficult for me to tell you where to run in these markets...
Straying from these names could land you in quicksand as the 4th quarter begins.
It is all about perception, and here are strong names to pick up on market weakness.
This downward action in the small biotech sector tends to happen often in the 'dog days' of summer.
Here are 3 ways to play these 3 stocks on earnings.